Evidence map›Paper›PMID 36808895›Full record

ReviewThoracic cancer2023

Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations.

Anita Sejben, Tamás Pancsa, László Tiszlavicz, József Furák, Dóra Paróczai, Tamás Zombori

Open access · goldAbstract readReview
In one paragraph

Review in Thoracic cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Epidemiological Trends in Mesothelioma Mortality in Colombia (1997-2022): A Retrospective National Study.International journal of environmental research and public health · 2025
    Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Anita SejbenDepartment of Pathology, University of Szeged, Szeged, Hungary.ORCID 0000-0002-9434-2989
Tamás PancsaDepartment of Pathology, University of Szeged, Szeged, Hungary.
László TiszlaviczDepartment of Pathology, University of Szeged, Szeged, Hungary.
József FurákDepartment of Surgery, University of Szeged, Szeged, Hungary.
Dóra ParóczaiDepartment of Pulmonology, University of Szeged, Deszk, Hungary.
Tamás ZomboriDepartment of Pathology, University of Szeged, Szeged, Hungary.
University of Szeged · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant mesothelioma (MM) is a rare tumor of mesothelial cells, with an increasing incidence both in developed and developing countries. MM has three major histological subtypes, in order of frequency, according to the World Health Organization (WHO) Classification of 2021: epithelioid, biphasic, and sarcomatoid MM. Distinction may be a challenging task for the pathologist, due to the unspecific morphology. Here, we present two cases of diffuse MM subtypes to emphasize the immunohistochemical (IHC) differences, and to facilitate diagnostic difficulties. In our first case of epithelioid mesothelioma, the neoplastic cells showed cytokeratin 5/6 (CK5/6), calretinin, and Wilms-tumor-1 (WT1) expression, while remaining negative with thyroid transcription factor-1 (TTF-1). BRCA1 associated protein-1 (BAP1) negativity was seen in the neoplastic cells' nucleus, reflecting loss of the tumor suppressor gene. In the second case of biphasic mesothelioma, expression of epithelial membrane antigen (EMA), CKAE1/AE3, and mesothelin was observed, while WT1, BerEP4, CD141, TTF1, p63, CD31, calretinin, and BAP1 expressions were not detected. Due to the absence of specific histological features, the differentiation between MM subtypes could be a challenging task. In routine diagnostic work, IHC may be the proper method in distinction. According to our results and literature data, CK5/6, mesothelin, calretinin, and Ki-67 should be applied in subclassification.

Indexed as

Lung NeoplasmsMesotheliomaMesothelioma, MalignantBiomarkers, TumorCalbindin 2Diagnosis, DifferentialHumansImmunohistochemistryMesothelinBiomarkers, TumorCalbindin 2Mesothelinasbestosepithelioidimmunohistochemistrymalignant mesotheliomasarcomatoid malignant mesothelioma

Identifiers

PMID36808895
PMCPMC10067356
OpenAlexW4321366260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.